Intravenous fat emulsions (1, 2, and 3 g/kg) were administered over 15 hr to 20 appropriate for gestational age premature infants with physiologic hyperbilirubinemia to determine the effect of fat infusions on the serum free fatty acid:albumin molar ratio (F/A) and on unbound bilirubin. Significant increases (p < 0.05) in F/A occurred with each increase in lipid dose in infants < 30 wk gestation, but not in infants ≥ 30 wk gestation. There was a direct linear correlation (r = 0.65, p < 0.001) between F/A ratio and unbound bilirubin (estimated fluorometrically by the ratio of albumin‐bound bilirubin/reserve bilirubin binding capacity, B/R). The largest increases in unbound bilirubin (albumin‐bound bilirubin/reserve bilirubin binding capacity) were seen in infants with F/ A > 4.0. The gestational age of infants with F/A > 4.0 was significantly less (p < 0.01) than infants with F/A < 4.0 (28.7 ± 0.47 us. 31.1 ± 0.40 wk, mean ± SEM). In 10/58 infusions there was a fall in unbound bilirubin, unrelated to birthweight, gestational age, postnatal age, however, during these infusions the end‐infusion F/A was ≥ 3.0. We conclude that 1 g/kg of lipid emulsion infused over a 15‐hr period has minimal risk of decreasing bilirubin binding in premature infants < 30 wk gestation. As doses of 2 or 3 g/kg are used, these infants may be at risk of decreased bilirubin binding, due to elevations in the F/A ratio. Monitoring of the F/A ratio may identify infants at risk for decreased bilirubin binding during lipid infusion and provide guidelines for determining the appropriate lipid dose. (Journal of Parenteral and Enteral Nutrition 9:144–147, 1985)
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.